A bipartisan group of congressional lawmakers is calling on the Trump administration to address the continued sale of illicit, compounded GLP-1 products, warning that consumers may be accessing ...

Real-world results for blockbuster weight-loss meds like Ozempic, Wegovy and Zepbound aren't as impressive as those promised ...

Canadian researchers find that taking semaglutide increases the chances of developing neovascular age-related macular ...

Investigators examined GLP-1 receptor agonist real-world effectiveness and safety in kidney transplant recipients with diabetes.

Nearly 75% of US adults are overweight or obese*, but the new GLP-1 pharmaceuticals are out of reach for many due to lack of ...

Weight loss drugs like Ozempic and Wegovy are used by over 15 million adults in the U.S., or 4.5% of the population. Despite ...

Scientists know the stomach talks to the brain, but two new studies from Rutgers Health researchers suggest the conversation ...

Researchers found that injectable GLP-1 receptor agonists for obesity tended to yield smaller reductions in weight in ...

Novo Nordisk's Q1 showed robust sales/EPS growth, fueled by soaring GLP-1 demand in a multi-billion dollar market. Read why I ...

A Cleveland Clinic study shows that semaglutide and tirzepatide – injectable GLP-1 drugs for obesity – produce smaller weight ...

Canada: A recent observational cohort study from Canada revealed that older diabetic patients taking GLP-1 receptor ...